 "Aurobindo Pharma gains on USFDA nod for hypertension drug")
Aurobindo Pharma is trading higher by nearly 3% to Rs 1,116 on NSE in early morning trade after the drug maker said it has received final approval from US health regulator to sell generic version of Valsartan tablets used for treatment of hypertension.
“The company has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Valsartan Tablets USP, 40mg, 80mg, 160mg and 320mg. The product is ready for launch,” Aurobindo Pharma said in a statement.
The product falls under the therapeutic category of CVS (Cardio Vascular) has a market size of approximately US$ 2 Billion for the twelve months ending October 2014 according to IMS, it added.
Aurobindo said now it has a total of 195 ANDA approvals (170 Final approvals including 7 from Aurolife Pharma LLC and 25 tentative approvals) from USFDA.
The stock opened at Rs 1,104 and touched a high of Rs 1,119 on NSE. A combined around 120,000 shares changed hands on the counter in first 10 minutes of trade on NSE and BSE.
“The company has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Valsartan Tablets USP, 40mg, 80mg, 160mg and 320mg. The product is ready for launch,” Aurobindo Pharma said in a statement.
The product falls under the therapeutic category of CVS (Cardio Vascular) has a market size of approximately US$ 2 Billion for the twelve months ending October 2014 according to IMS, it added.
Aurobindo said now it has a total of 195 ANDA approvals (170 Final approvals including 7 from Aurolife Pharma LLC and 25 tentative approvals) from USFDA.
The stock opened at Rs 1,104 and touched a high of Rs 1,119 on NSE. A combined around 120,000 shares changed hands on the counter in first 10 minutes of trade on NSE and BSE.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%